RT Journal Article
T1 [Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry].
T2 Fibrilación auricular en pacientes con COVID-19. Utilidad de la puntuación CHA2DS2-VASc: un análisis del registro internacional HOPE COVID-19.
A1 Uribarri, Aitor
A1 Núñez-Gil, Iván J
A1 Aparisi, Álvaro
A1 Arroyo-Espliguero, Ramón
A1 Maroun Eid, Charbel
A1 Romero, Rodolfo
A1 Becerra-Muñoz, Víctor M
A1 Feltes, Gisela
A1 Molina, María
A1 García-Aguado, Marcos
A1 Cerrato, Enrico
A1 Capel-Astrua, Thamar
A1 Alfonso-Rodríguez, Emilio
A1 Castro-Mejía, Alex F
A1 Raposeiras-Roubín, Sergio
A1 Espejo, Carolina
A1 Pérez-Solé, Nerea
A1 Bardají, Alfredo
A1 Marín, Francisco
A1 Fabregat-Andrés, Óscar
A1 D'ascenzo, Fabrizio
A1 Santoro, Francesco
A1 Akin, Ibrahim
A1 Estrada, Vicente
A1 Fernández-Ortiz, Antonio
A1 Macaya, Carlos
A1 en representación de los investigadores HOPE COVID-19, 
K1 Atrial fibrillation
K1 Bleeding
K1 CHA2DS2-VASc
K1 COVID-19
K1 Mortality
K1 Prognosis
K1 Registry
K1 SARS-CoV-2
AB Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2. Atrial fibrillation (AF) is common in acute situations, where it is associated with more complications and higher mortality. Analysis of the international HOPE registry (NCT04334291). The objective was to assess the prognostic information of AF in COVID-19 patients. A multivariate analysis and propensity score matching were performed to assess the relationship between AF and mortality. We also evaluated the impact on mortality and embolic events of the CHA2DS2-VASc score in these patients. Among 6217 patients enrolled in the HOPE registry, 250 had AF (4.5%). AF patients had a higher prevalence of cardiovascular risk factors and comorbidities. After propensity score matching, these differences were attenuated. Despite this, patients with AF had a higher incidence of in-hospital complications such as heart failure (19.3% vs 11.6%, P = .021) and respiratory insufficiency (75.9% vs 62.3%, P = .002), as well as a higher 60-day mortality rate (43.4% vs 30.9%, P = .005). On multivariate analysis, AF was independently associated with higher 60-day mortality (hazard ratio, 1.234; 95%CI, 1.003-1.519). CHA2DS2-VASc score acceptably predicts 60-day mortality in COVID-19 patients (area ROC, 0.748; 95%CI, 0.733-0.764), but not its embolic risk (area ROC, 0.411; 95%CI, 0.147-0.675). AF in COVID-19 patients is associated with a higher number of complications and 60-day mortality. The CHA2DS2-VASc score may be a good risk marker in COVID patients but does not predict their embolic risk.
YR 2021
FD 2021-03-02
LK http://hdl.handle.net/10668/17324
UL http://hdl.handle.net/10668/17324
LA es
DS RISalud
RD Apr 7, 2025